Apellis Pharmaceuticals, Inc.
APLSDelisted May 14, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted on May 14, 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Apellis Pharmaceuticals, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 284
- +32 vs. Q3 2023
- Shares held
- 113.8M
- −76.3K (−0.1%) vs. Q3 2023
- Total value
- $6.82B
- +$2.48B (+57.1%) vs. Q3 2023
- New holders
- 65
- 79 more added
- Sold out
- 33
- 110 more reduced
4 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APLS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $10.2K |
| Q1 2026 | 324 | $5.56B |
| Q4 2025 | 280 | $3.17B |
| Q3 2025 | 273 | $2.77B |
| Q2 2025 | 247 | $2.28B |
| Q1 2025 | 255 | $2.80B |
| Q4 2024 | 260 | $4.04B |
| Q3 2024 | 265 | $3.41B |
| Q2 2024 | 263 | $4.43B |
| Q1 2024 | 302 | $6.65B |
| Q4 2023 | 284 | $6.82B |
| Q3 2023 | 256 | $4.34B |
| Q2 2023 | 317 | $9.71B |
| Q1 2023 | 282 | $7.28B |
| Q4 2022 | 244 | $5.20B |
| Q3 2022 | 250 | $6.66B |
| Q2 2022 | 212 | $4.15B |
| Q1 2022 | 212 | $4.62B |
| Q4 2021 | 187 | $3.83B |
| Q3 2021 | 181 | $2.29B |
| Q2 2021 | 205 | $4.08B |
| Q1 2021 | 175 | $2.80B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Apellis Pharmaceuticals, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jump Financial, LLC | 0 | $0 | 0.00% | −9,029−100.0% | Sold out |
| Pictet & Cie (Europe) SA | 0 | $0 | 0.00% | −6,825−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −6,802−100.0% | Sold out |
| Inspire Advisors, LLC | 0 | $0 | 0.00% | −6,115−100.0% | Sold out |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −6,100−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −6,083−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −3,806−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −3,500−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −2,949−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −1,200−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −450−100.0% | Sold out |
| National Bank of Canada | 0 | $0 | 0.00% | −393−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Baker Avenue Asset Management, LP | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Larson Financial Group LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Tfo-TDC, LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Innovis Asset Management LLC | – | – | – | – | Not filed |
| Virginia Retirement Systems Et Al | – | – | – | – | Not filed |
| Jacob Asset Management of New York LLC | – | – | – | – | Not filed |
| Steward Financial Group LLC | – | – | – | – | Not filed |